Literature DB >> 34178206

What morphology can teach us about renal cell carcinoma clonal evolution.

Payal Kapur1,2,3, Alana Christie3, Satwik Rajaram4, James Brugarolas5,3.   

Abstract

While cancer is a clonal process, cumulative evidence suggest that tumors are rather heterogenous and are composed of multiple genetically-distinct subclones that arise at different times and either persist and co-exist, expand and evolve, or are eliminated. A paradigm of tumor heterogeneity is renal cell carcinoma (RCC). By exploiting morphological traits and building upon a framework around three axes (architecture, cytology and the microenvironment), we review recent advances in our understanding of RCC evolution leading to an integrated molecular genetic and morphologic evolutionary model with both prognostic and therapeutic implications. The ability to predict cancer evolution may have profound implications for clinical care and is central to oncology.

Entities:  

Keywords:  Kidney cancer; ccRCC; genomics; intratumoral heterogeneity; morphology; ontology; tumor evolution

Year:  2020        PMID: 34178206      PMCID: PMC8232548     

Source DB:  PubMed          Journal:  Kidney Cancer J        ISSN: 1933-0863


  43 in total

1.  Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade.

Authors:  Yi-Feng Gu; Shannon Cohn; Alana Christie; Tiffani McKenzie; Nicholas Wolff; Quyen N Do; Ananth J Madhuranthakam; Ivan Pedrosa; Tao Wang; Anwesha Dey; Meinrad Busslinger; Xian-Jin Xie; Robert E Hammer; Renée M McKay; Payal Kapur; James Brugarolas
Journal:  Cancer Discov       Date:  2017-05-04       Impact factor: 39.397

2.  Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma.

Authors:  Axel Bex; Laurence Albiges; Börje Ljungberg; Karim Bensalah; Saeed Dabestani; Rachel H Giles; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas B Lam; Lorenzo Marconi; Axel S Merseburger; Michael Staehler; Alessandro Volpe; Thomas Powles
Journal:  Eur Urol       Date:  2016-12-13       Impact factor: 20.096

Review 3.  Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention.

Authors:  Steffen Weikert; Börje Ljungberg
Journal:  World J Urol       Date:  2010-06       Impact factor: 4.226

4.  A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma.

Authors:  Sharanya Sivanand; Samuel Peña-Llopis; Hong Zhao; Blanka Kucejova; Patrick Spence; Andrea Pavia-Jimenez; Toshinari Yamasaki; David J McBride; Jessica Gillen; Nicholas C Wolff; Lorraine Morlock; Yair Lotan; Ganesh V Raj; Arthur Sagalowsky; Vitaly Margulis; Jeffrey A Cadeddu; Mark T Ross; David R Bentley; Wareef Kabbani; Xian-Jin Xie; Payal Kapur; Noelle S Williams; James Brugarolas
Journal:  Sci Transl Med       Date:  2012-06-06       Impact factor: 17.956

5.  Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.

Authors:  James J Hsieh; David Chen; Patricia I Wang; Mahtab Marker; Almedina Redzematovic; Ying-Bei Chen; S Duygu Selcuklu; Nils Weinhold; Nancy Bouvier; Kety H Huberman; Umesh Bhanot; Michael S Chevinsky; Parul Patel; Patrizia Pinciroli; Helen H Won; Daoqi You; Agnes Viale; William Lee; A Ari Hakimi; Michael F Berger; Nicholas D Socci; Emily H Cheng; Jennifer Knox; Martin H Voss; Maurizio Voi; Robert J Motzer
Journal:  Eur Urol       Date:  2016-10-15       Impact factor: 20.096

6.  Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.

Authors:  Michael L Nickerson; Erich Jaeger; Yangu Shi; Jeffrey A Durocher; Sunil Mahurkar; David Zaridze; Vsevolod Matveev; Vladimir Janout; Hellena Kollarova; Vladimir Bencko; Marie Navratilova; Neonilia Szeszenia-Dabrowska; Dana Mates; Anush Mukeria; Ivana Holcatova; Laura S Schmidt; Jorge R Toro; Sara Karami; Rayjean Hung; Gary F Gerard; W Marston Linehan; Maria Merino; Berton Zbar; Paolo Boffetta; Paul Brennan; Nathaniel Rothman; Wong-Ho Chow; Frederic M Waldman; Lee E Moore
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

7.  Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.

Authors:  Rana R McKay; Nils Kroeger; Wanling Xie; Jae-Lyun Lee; Jennifer J Knox; Georg A Bjarnason; Mary J MacKenzie; Lori Wood; Sandy Srinivas; Ulka N Vaishampayan; Sun-Young Rha; Sumanta K Pal; Frede Donskov; Srinivas K Tantravahi; Brian I Rini; Daniel Y C Heng; Toni K Choueiri
Journal:  Eur Urol       Date:  2013-08-15       Impact factor: 20.096

8.  Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis.

Authors:  Judit Espana-Agusti; Anne Warren; Su Kit Chew; David J Adams; Athena Matakidou
Journal:  Nat Commun       Date:  2017-12-11       Impact factor: 14.919

9.  Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type.

Authors:  Qi Cai; Alana Christie; Satwik Rajaram; Qinbo Zhou; Ellen Araj; Suneetha Chintalapati; Jeffrey Cadeddu; Vitaly Margulis; Ivan Pedrosa; Dinesh Rakheja; Renee M McKay; James Brugarolas; Payal Kapur
Journal:  EBioMedicine       Date:  2019-12-16       Impact factor: 8.143

10.  Clinical Impact of Pancreatic Metastases from Renal Cell Carcinoma: A Multicenter Retrospective Analysis.

Authors:  Paolo Grassi; Ludovic Doucet; Palma Giglione; Viktor Grünwald; Bohuslav Melichar; Luca Galli; Ugo De Giorgi; Roberto Sabbatini; Cinzia Ortega; Matteo Santoni; Aristotelis Bamias; Elena Verzoni; Lisa Derosa; Hana Studentova; Monica Pacifici; Jorgelina Coppa; Vincenzo Mazzaferro; Filippo de Braud; Camillo Porta; Bernard Escudier; Giuseppe Procopio
Journal:  PLoS One       Date:  2016-04-11       Impact factor: 3.240

View more
  4 in total

1.  Development and validation of a vascularity-based architectural classification for clear cell renal cell carcinoma: correlation with conventional pathological prognostic factors, gene expression patterns, and clinical outcomes.

Authors:  Chisato Ohe; Takashi Yoshida; Mahul B Amin; Naho Atsumi; Junichi Ikeda; Kazuho Saiga; Yuri Noda; Yoshiki Yasukochi; Riuko Ohashi; Haruyuki Ohsugi; Koichiro Higasa; Hidefumi Kinoshita; Koji Tsuta
Journal:  Mod Pathol       Date:  2021-11-30       Impact factor: 7.842

2.  Intratumoral Resolution of Driver Gene Mutation Heterogeneity in Renal Cancer Using Deep Learning.

Authors:  Paul H Acosta; Vandana Panwar; Vipul Jarmale; Alana Christie; Jay Jasti; Vitaly Margulis; Dinesh Rakheja; John Cheville; Bradley C Leibovich; Alexander Parker; James Brugarolas; Payal Kapur; Satwik Rajaram
Journal:  Cancer Res       Date:  2022-08-03       Impact factor: 13.312

3.  PBRM1 Immunohistochemical Expression Profile Correlates with Histomorphological Features and Endothelial Expression of Tumor Vasculature for Clear Cell Renal Cell Carcinoma.

Authors:  Kazuho Saiga; Chisato Ohe; Takashi Yoshida; Haruyuki Ohsugi; Junichi Ikeda; Naho Atsumi; Yuri Noda; Yoshiki Yasukochi; Koichiro Higasa; Hisanori Taniguchi; Hidefumi Kinoshita; Koji Tsuta
Journal:  Cancers (Basel)       Date:  2022-02-20       Impact factor: 6.639

4.  Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma.

Authors:  Michael T Serzan; Michael B Atkins
Journal:  J Cancer Metastasis Treat       Date:  2021-07-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.